Oxford Endovascular one of the Top 50 start-ups in the MedTech Innovator competition

By Nicky Godding

28 June 2022

Share

The Business Magazine article image for: Oxford Endovascular one of the Top 50 start-ups in the MedTech Innovator competition

MedTech Innovator, the world’s largest accelerator of medical technology companies, has revealed Oxford Endovascular as one of its 50 companies selected to participate in the organisation’s flagship four-month Accelerator program, featuring medical device, diagnostic, and digital health technologies from around the globe. As 2022 Cohort members, these startups will get access to leading medtech manufacturers, providers, investors, and other industry stakeholders. At the conclusion of the program, MedTech Innovator will award $500,000 in cash and in-kind prizes in the final competition held at The MedTech Conference, in Boston later this year.

Paul Grand, CEO of MedTech Innovator, said: “Over the past nine years, MedTech Innovator has established a unique track record of identifying and supporting leading startups, with 95% of our graduates either still in business or having been acquired.

"The 2022 MedTech Innovator Cohort represents a diverse and focused group of innovators, and we are excited to work with them alongside our corporate partners and industry advisors to ensure their success in addressing important unmet needs and improving patient care.”

Oxford Endovascular Ltd is a spin-out from Oxford University, working to prevent brain haemorrhage by curing brain aneurysms, a condition that affects one in 50 persons.

Its OxiFlow is a novel, next generation flow-diverter, that diverts blood flow away from intracranial aneurysms at risk of rupture. It places more accurately and safely than existing devices, reducing the risk of complications. It conforms better to blood vessels making more patients treatable.

Invented by a world-renowned physician who pioneered the treatment of aneurysms over the last 30 years and an expert in ‘origami engineering’, it has patents in Europe, US, China & Japan.

The company has raised more than $10m to support its development including winning a prestigious Horizon 2020 grant from the European Union following extensive due diligence by medical, industry and investor experts.

Targeting a market over $1 billion, that is growing rapidly, Oxford Endovascular is poised for significant increased value as it addresses unmet clinical needs.

Oxford Endovascular is one of just three companies from the UK included in the list. The other two are 52 North Health in Cambridge and Phagenesis in Manchester.

By Nicky Godding

Nicky Godding is editor of The Business Magazine. Before her journalism career, she worked mainly in public relations moving into writing when she was invited to launch Retail Watch, a publication covering retail and real estate across Europe.

After some years of constant travelling, she tucked away her passport and concentrated on business writing, co-founding a successful regional business magazine. She has interviewed some of the UK’s most successful entrepreneurs who have built multi-million-pound businesses and reported on many science and technology firsts.

She reports on the region’s thriving business economy from start-ups, family businesses and multi-million-pound corporations, to the professionals that support their growth and the institutions that educate the next generation of business leaders.